Based on the forecasted data, the respiratory system medicine sales in Türkiye are as follows:
- 2024: 7.51 Billion New Turkish Liras
- 2025: 8.28 Billion New Turkish Liras
- 2026: 9.04 Billion New Turkish Liras
- 2027: 9.79 Billion New Turkish Liras
- 2028: 10.54 Billion New Turkish Liras
Year-on-year variations (in percentage):
- 2025: [(8.28 - 7.51) / 7.51] * 100 = 10.26%
- 2026: [(9.04 - 8.28) / 8.28] * 100 = 9.18%
- 2027: [(9.79 - 9.04) / 9.04] * 100 = 8.29%
- 2028: [(10.54 - 9.79) / 9.79] * 100 = 7.66%
Compound Annual Growth Rate (CAGR) from 2024 to 2028: [((10.54 / 7.51)^(1/4)) - 1] * 100 ≈ 8.99%
The trend demonstrates a consistent growth rate in sales for respiratory system medicines in Türkiye, with an average annual increase of around 8.99%. This indicates robust market potential influenced by factors such as rising awareness of respiratory health and increasing incidences of respiratory diseases.
Future trends to watch: The emergence of innovative treatments and increasing healthcare expenditure are expected to further drive market growth. Additionally, monitoring policy changes and advancements in biotechnology could significantly affect future sales dynamics.
